Thioaptamers enable discovery of physiological pathways and new therapeutic strategies

• US 20050118611A1
• Filed: 07/23/2004
• Published: 06/02/2005
• Est. Priority Date: 07/24/2003
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Luxon, Bruce A., Gorenstein, David G.
• Application Number:
  US10/898,470
• Publication Number:
  US 20050118611A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2310/13 Decoys
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/315 Phosphorothioates

Abstract

A system and method for determining the effect of a target molecule within a physiological pathway is disclosed in which a thioaptamer is used to affect a detectable activity of the physiological pathway in a cell or cell fragment.

Claims

1. A method of disrupting selectively a target molecule within a physiological pathway comprising the steps of:

characterizing a detectable activity of the physiological pathway;

identifying a thioaptamer that modifies the activity of the target molecule of the physiological pathway; and

determining the extent of the modification to the activity of the physiological pathway in the presence of the thioaptamer.

2. The method of claim 1, wherein between one to about eight of the phosphate links of the thioaptamer are thio-modified.

3. The method of claim 1, wherein between one to about eight of the phosphate links of both strands of the thioaptamer are thio-modified.

4. The method of claim 1, wherein the thioaptamer is single stranded.

5. The method of claim 1, wherein the thioaptamer comprises RNA.

6. The method of claim 1, wherein the thioaptamer comprises siRNA.

7. The method of claim 1, wherein the target molecule is selected from the group comprising a nucleic acid, a protein, a complex of proteins and a complex of one or more proteins and one or more nucleic acids.

8. The method of claim 1, wherein the detectable activity measured comprises a chemical assay, a biological assay, a photometric, a spectrophotometric, a colorimetric, a chemiluminescent, a fluorescent, a radioactive, a mass spectrometric, a electrophoretic, magnetic resonance imaging, nuclear magnetic resonance and combinations thereof.

9. The method of claim 1, wherein no more than three adjacent phosphate sites of the thioaptamer are replaced with phosphorothioate groups.

10. The method of claim 1, wherein at least a portion of non-adjacent dA, dC, dG, or dT phosphate sites of the thioaptamer are replaced with phosphorothioate groups.

11. The method of claim 1, wherein all of the non-adjacent dA, dC, dG, and dT phosphate sites of the thioaptamer are replaced with phosphorodithioate groups.

12. The method of claim 1, wherein the thioaptamer is between about 12 and about 60 bases in length.

13. The method of claim 1, wherein substantially all non-adjacent phosphate sites of the thioaptamer are replaced with one or more phosphorothioate groups.

14. The method of claim 1, wherein the thioaptamer is defined further as being double-stranded.

15. The method of claim 1, wherein one or more modified nucleotides of the thioaptamer are selected from the group consisting of dATP(α

S), dTTP(α

S), dCTP(α

S), dGTP(α

S), rUTP (α

S), rATP(α

S), rCTP(α

S), rGTP(α

S), d ATP(α

S₂), dTTP(α

S₂), dCTP(α

S₂), dGTP(α

S₂), rATP(α

S₂), rCTP(α

S₂), rGTP(α

S₂) and rUTP(α

S₂) or modifications thereof.

16. The method of claim 1, wherein the thioaptamer is selected by the steps of:

synthesizing a random phosphodiester oligonucleotide combinatorial library using a mix of four nucleotides, wherein at least a portion of at least one of the nucleotides in the mix is thiophosphate-modified, to form a thioaptamer combinatorial library;

contacting the thioaptamer combinatorial library with the target molecule isolating a subset of thioaptamers binding to the target molecule.

17. The method of claim 16, wherein the subset of thioaptamers is sequenced.

18. The method of claim 1, wherein the physiological pathway is selected from the group consisting of biosynthesis of cofactors prosthetic groups and carriers (lipoate synthesis, riboflavin synthesis pyridine nucleotide synthesis);

the biosynthesis of the cell envelopes (membranes, lipoproteins, porins, surface polysaccharides, lipopolysaccharides, antigens and surface structures);

cellular processes including cell division, chaperones, detoxification, protein secretion, central intermediary metabolism (energy production of phosphorus compounds);

energy metabolism including aerobic, anaerobic, ATP proton motive force interconversions, electron transport, glycolysis triose phosphate pathway, pyruvate dehydrogenase, sugar metabolism;

purine, pyrimidine nucleotide synthesis, 2′

-deoxyribonucleotide synthesis, nucleotide and nucleoside interconversion, salvage of nucleoside and nucleotides, sugar-nucleotide biosynthesis and conversion;

regulatory functions including transcriptional and translational controls, DNA replication including degradation of DNA, DNA replication, restriction modification, recombination and repair;

transcription including degradation of DNA, DNA-dependent RNA polymerase and transcription factors;

RNA processing;

translation including amino acyl tRNA synthetases, degradation of peptides and glycopeptides, protein modification, ribosome synthesis and modification, tRNA modification;

translation factors transport and binding proteins including amino acid, peptide, amine carbohydrate, organic alcohol, organic acid and cation transport; and

other systems for the adaptation, specific function or survival of an artificial organism and combinations thereof.

19. The method of claim 1, wherein the physiological pathway comprises cytokine release.

20. The method of claim 1, wherein the target molecule comprises a nuclear regulatory factor.

21. The method of claim 1, wherein the target molecule comprises a nuclear regulatory factor selected from the group consisting of NF IL-6, NF-κ

B, AP-1 and combinations thereof.

22. A method of testing a chemical agent comprising the steps of:

exposing a cell having a measurable biochemical activity to a thioaptamer that modifies the activity of a target molecule;

contacting at least a portion of the cell with the chemical agent; and

measuring the effect that the chemical agent has on the measurable biochemical activity.

23. The method of claim 22, wherein between one to about eight of the phosphate links of the thioaptamer are thio-modified.

24. The method of claim 22, wherein between one to about eight of the phosphate links of both strands of the thioaptamer are thio-modified.

25. The method of claim 22, wherein the thioaptamer is single stranded.

26. The method of claim 22, wherein the thioaptamer comprises RNA.

27. The method of claim 22, wherein the thioaptamer comprises a dsRNA.

28. The method of claim 22, wherein the target molecule is selected from the group comprising a nucleic acid, a protein, a complex of proteins and a complex of one or more proteins and one or more nucleic acids.

29. The method of claim 22, wherein the measurable biochemical activity is determined by an assay that is chemical, biological, photometric, spectrophotometric, calorimetric, chemiluminescent, fluorescent, radioactive, mass spectrometric, electrophoretic, magnetic resonance imaging, nuclear magnetic resonance and combinations thereof.

30. The method of claim 22, wherein the thioaptamer has SEQ ID NOS:

1-9.

31. The method of claim 22, wherein the modified nucleotide aptamer comprises one or more phosphorothioate or phosphordithioate linkages.

32. The method of claim 22, wherein one or more modified nucleotides of the thioaptamer are selected from the group consisting of dATP(α

S), dTTP(α

S), dCTP(α

S), dGTP(α

S), rUTP (α

S), rATP(α

S), rCTP(α

S), rGTP(α

S), d ATP(α

S₂), dTTP(α

S₂), dCTP(α

S₂), dGTP(α

S₂), rATP(α

S₂), rCTP(α

S₂), rGTP(α

S₂) and rUTP(α

S₂) or modifications thereof.

33. The method of claim 22, wherein the measurable biochemical activity is selected from the group consisting of biosynthesis of cofactors prosthetic groups and carriers (lipoate synthesis, riboflavin synthesis pyridine nucleotide synthesis);

the biosynthesis of the cell envelopes (membranes, lipoproteins, porins, surface polysaccharides, lipopolysaccharides, antigens and surface structures);

cellular processes including cell division, chaperones, detoxification, protein secretion, central intermediary metabolism (energy production of phosphorus compounds);

energy metabolism including aerobic, anaerobic, ATP proton motive force interconversions, electron transport, glycolysis triose phosphate pathway, pyruvate dehydrogenase, sugar metabolism;

purine, pyrimidine nucleotide synthesis, 2′

-deoxyribonucleotide synthesis, nucleotide and nucleoside interconversion, salvage of nucleoside and nucleotides, sugar-nucleotide biosynthesis and conversion;

regulatory functions including transcriptional and translational controls, DNA replication including degradation of DNA, DNA replication, restriction modification, recombination and repair;

transcription including degradation of DNA, DNA-dependent RNA polymerase and transcription factors;

RNA processing;

translation including amino acyl tRNA synthetases, degradation of peptides and glycopeptides, protein modification, ribosome synthesis and modification, tRNA modification;

translation factors transport and binding proteins including amino acid, peptide, amine carbohydrate, organic alcohol, organic acid and cation transport; and

other systems for the adaptation, specific function or survival of an artificial organism and combinations thereof.

34. The method of claim 22, wherein the measurable biochemical activity comprises cytokine release.

35. The method of claim 22, wherein the target molecule comprises a nuclear regulatory factor.

36. The method of claim 22, wherein the target molecule comprises a nuclear regulatory factor selected from the group consisting of NF IL-6, NF-κ

B, AP-1 and combinations thereof.

37. The method of claim 22, wherein the cell is from an animal knock-out, knock-in, transgenic, over-expressing transgenic, under-expressing-transgenic, conditional knockout, mutant, chimera or combinations thereof.

38. A system for testing the biological effects of a molecule comprising:

at least a portion of a cell comprising a target molecule and a measurable biochemical activity;

a thioaptamer that modifies the activity of the target molecule that is added to the cell; and

a biochemical activity detection device that records differences in the measurable biochemical activity of the cell upon exposure to the molecule.

39. The system of claim 38, wherein the measurable biochemical activity is selected from the group consisting of biosynthesis of cofactors prosthetic groups and carriers (lipoate synthesis, riboflavin synthesis pyridine nucleotide synthesis);

the biosynthesis of the cell envelopes (membranes, lipoproteins, porins, surface polysaccharides, lipopolysaccharides, antigens and surface structures);

cellular processes including cell division, chaperones, detoxification, protein secretion, central intermediary metabolism (energy production of phosphorus compounds);

energy metabolism including aerobic, anaerobic, ATP proton motive force interconversions, electron transport, glycolysis triose phosphate pathway, pyruvate dehydrogenase, sugar metabolism;

purine, pyrimidine nucleotide synthesis, 2′

-deoxyribonucleotide synthesis, nucleotide and nucleoside interconversion, salvage of nucleoside and nucleotides, sugar-nucleotide biosynthesis and conversion;

regulatory functions including transcriptional and translational controls, DNA replication including degradation of DNA, DNA replication, restriction modification, recombination and repair;

transcription including degradation of DNA, DNA-dependent RNA polymerase and transcription factors;

RNA processing;

translation including amino acyl tRNA synthetases, degradation of peptides and glycopeptides, protein modification, ribosome synthesis and modification, tRNA modification;

translation factors transport and binding proteins including amino acid, peptide, amine carbohydrate, organic alcohol, organic acid and cation transport; and

other systems for the adaptation, specific function or survival of an artificial organism and combinations thereof.

40. The system of claim 38, wherein the measurable biochemical activity comprises cytokine release.

41. The system of claim 38, wherein the target molecule comprises a nuclear regulatory factor.

42. The system of claim 38, wherein the target molecule comprises a nuclear regulatory factor selected from the group consisting of NF IL-6, NF-κ

B, AP-1 and combinations thereof.

43. The system of claim 38, wherein the cell is from an animal knock-out, knock-in, transgenic, over-expressing transgenic, under-expressing-transgenic, conditional knockout, mutant, chimera or combinations thereof.

44. The system of claim 38, wherein the thioaptamer comprises RNA.

45. The system of claim 38, wherein the thioaptamer comprises siRNA.

46. The system of claim 38, wherein the target molecule is selected from the group comprising a nucleic acid, a protein, a complex of proteins and a complex of one or more proteins and one or more nucleic acids.

47. The system of claim 38, wherein the detectable activity measured comprises a chemical assay, a biological assay, a photometric, a spectrophotometric, a calorimetric, a chemiluminescent, a fluorescent, a radioactive, a mass spectrometric, a electrophoretic, magnetic resonance imaging, nuclear magnetic resonance and combinations thereof.